AN2 Therapeutics Reports Q2 Earnings, Net Loss Improves to $6.5M
ByAinvest
Thursday, Aug 14, 2025 3:35 am ET1min read
ANTX--
AN2 Therapeutics reported a Q2 net loss of $6.5 million, a significant improvement from $14.4 million in the same period last year. Operating expenses decreased to $7.2 million from $15.9 million. The company has $71.2 million in cash, down from $92.1 million at the end of 2024, but believes it can fund operations for at least the next 12 months. AN2 Therapeutics is focused on advancing its pipeline of boron-based compounds and securing additional funding to support its research and development activities.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet